investors & media
NASDAQ: (common stock)
Data Provided by Refinitiv. Minimum 15 minutes delayed.
EMA’s PRIME program designed to optimize development and expedite evaluation of innovative medicines for patients with high unmet need CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 23, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell diseaseRead more
FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma PRINCETON, N.J. , & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 22, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc .Read more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2020 Wells Fargo Virtual Healthcare Conference , Thursday, September 10 , at 4:00 pm ET MorganRead more